Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 9/20 | 0.44 |
| ▸ | MMP13 | P45452 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6916309 | 0.91 | MMP13 (0.55) | TRPA1MMP13MAPTGAAPTGER4 | |
| SCHEMBL6735506 | 0.90 | MAPT (0.41) | TRPA1MMP13MAPTGAAKLKB1 | |
| SCHEMBL6474162 | 0.85 | MAPT (0.56) | TRPA1MAPTGAA | |
| SCHEMBL6280233 | 0.84 | MAPT (0.51) | TRPA1MMP13MAPTGAASMN1; SMN2 | |
| SCHEMBL6462371 | 0.84 | MMP13 (0.52) | TRPA1MMP13MAPTSLC22A8PTGER4 | |
| SCHEMBL7021132 | 0.84 | TRPA1 (0.57) | TRPA1MMP13MAPTSLC22A8PTGER4 | |
| SCHEMBL7038032 | 0.83 | TRPA1 (0.56) | TRPA1MMP13MAPTSLC22A8PTGER4 | |
| SCHEMBL7032480 | 0.83 | MAPT (0.51) | TRPA1MAPTGAA | |
| SCHEMBL6272722 | 0.82 | NR1H4 (0.51) | MAPTPPARGSMN1; SMN2 | |
| SCHEMBL6430172 | 0.82 | TRPA1 (0.48) | TRPA1MMP13MAPTGAASLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | claimed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | TRPA1 3888/4885MMP13 1/4885MAPT 4800/4885 |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | TRPA1 982/4885MMP13 1/4885MAPT 1345/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | TRPA1 671/4885MMP13 1/4885MAPT 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.